Sampath Kumar

Senior Director and Head of Cell Line Development at Takeda

Advisor

Sampath Kumar heads the Cell Line Development Group that develops clinical-grade cell lines to produce protein therapeutics and is developing similar technologies to stably produce viral vectors for cell therapy. He earned a Ph.D. in biology from the National University of Singapore, and conducted post-doctoral research at The Lawson Health Research Institute (London, Ontario, Canada) and the University of Maryland Biotechnology Institute (Baltimore, MA), both in molecular reproductive endocrinology. His 20-year biopharmaceutical industry career spans CuraGen, Wyeth, Pfizer, Biogen and Takeda.